Summit Therapeutics (SMMT) Assets Average (2016 - 2025)
Historic Assets Average for Summit Therapeutics (SMMT) over the last 10 years, with Q3 2025 value amounting to $292.9 million.
- Summit Therapeutics' Assets Average fell 3065.46% to $292.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $292.9 million, marking a year-over-year decrease of 3065.46%. This contributed to the annual value of $319.3 million for FY2024, which is 2636.41% down from last year.
- Per Summit Therapeutics' latest filing, its Assets Average stood at $292.9 million for Q3 2025, which was down 3065.46% from $353.9 million recorded in Q2 2025.
- In the past 5 years, Summit Therapeutics' Assets Average registered a high of $469.2 million during Q4 2024, and its lowest value of $106.1 million during Q2 2022.
- For the 5-year period, Summit Therapeutics' Assets Average averaged around $253.7 million, with its median value being $227.9 million (2023).
- Its Assets Average has fluctuated over the past 5 years, first skyrocketed by 29986.12% in 2023, then plummeted by 5868.3% in 2024.
- Summit Therapeutics' Assets Average (Quarter) stood at $121.0 million in 2021, then skyrocketed by 238.57% to $409.7 million in 2022, then plummeted by 48.58% to $210.7 million in 2023, then surged by 122.68% to $469.2 million in 2024, then plummeted by 37.58% to $292.9 million in 2025.
- Its Assets Average was $292.9 million in Q3 2025, compared to $353.9 million in Q2 2025 and $409.7 million in Q1 2025.